ClinicalTrials.gg
CompletedNCT02085538Updated Apr 30, 2018

Study Of Palbociclib (PD-0332991) In Renal Impairment

A Phase 1 interventional study of palbociclib and palbociclib in Renal Impairment, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
17th of 36
31 · median 30
Started
2014
the only one that year
Phase 1
23 of 37
2 open now
Registered
20th of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 17th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2014, is one of 23 in phase 1, and was the 20th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

Since the amount of palbociclib eliminated in urine is 6.9%, renal impairment is not expected to have much impact on palbociclib. However, the Federal Drug Administration (FDA) Guidance recommends a study in subjects with renal impairment when the drug is likely to be used in patients with impaired renal function. Palbociclib is intended for chronic use in cancer patients who may have some degree of impaired renal function.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • renal impairment
  • AUC
  • Cmax
  • palbociclib
  • normal matched subjects
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Personally signed and dated document.
  • Renal function calculated by the equation: normal function (CLcr >=90 mL/min), mild: CLcr >=60 mL/min and \<90 mL/min, moderate: CLcr >=30 mL/min and \<60 mL/min, severe: CLcr \<30 mL/min but not requiring hemodialysis.
  • Subjects with normal renal function matched for age, weight, gender and race to subjects in impaired renal function groups.

Exclusion criteria

Exclusion Criteria:

  • Any condition possibly affecting drug absorption.
  • Renal allograft recipients.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Normal Renal Function

    Drug: palbociclib

  • Experimental
    Mild Renal Impairment

    Drug: palbociclib

  • Experimental
    Moderate Renal Impairment

    Drug: palbociclib

  • Experimental
    Severe Renal Impairment

    Drug: palbociclib

Interventions

  • palbociclib 125 mg oral capsule with food once

  • palbociclib 125 mg oral capsule with food once

  • palbociclib 125 mg oral capsule with food once

  • palbociclib 125 mg oral capsule with food once

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]

    AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).

    Time frame: 8 days

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 8 days

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)

    Time frame: 8 days

  2. Apparent Oral Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.

    Time frame: 8 days

  3. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 8 days

  4. Apparent Volume of Distribution (Vz/F)

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 8 days

  5. Plasma Decay Half-Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 8 days

  6. Unbound Apparent Oral Clearance (CLu/F)

    Clearance of unbound drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the oral bioavailability. Unbound drug clearance is a quantitative measure of the rate at which an unbound drug substance is removed from the blood.

    Time frame: 8 days

  7. "Unbound Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)u]"

    AUC (0 - ∞)u= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞)u for unbound drug. It is obtained from AUC (0 - t)u plus AUC (t - ∞)u for unbound drug.

    Time frame: 8 days

  8. Unbound Maximum Observed Plasma Concentration (Cmaxu)

    Cmaxu is the highest measured unbound plasma concentration during the dosing interval.

    Time frame: 8 days

  9. "Unbound Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClastu)"

    Area under the plasma concentration time-curve from zero to the last measured concentration (AUClastu) for unbound drug.

    Time frame: 8 days

  10. fraction of unbound drug in plasma (fu)

    fraction of drug in plasma or tissues that is not bound to plasma or tissue proteins.

    Time frame: 8 days

  11. Unbound Apparent Volume of Distribution (Vzu/F)

    Unbound Volume of distribution is defined as the theoretical volume in which the total unbound amount of drug would need to be uniformly distributed to produce the desired unbound plasma concentration of a drug. Unbound Apparent volume of distribution after oral dose (Vzu/F) is influenced by the fraction absorbed.

    Time frame: 8 days

07

Study locations

3 sites
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Prism Research
    Saint Paul, Minnesota 55114, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in May 2016, 24 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 24 months is above that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2014
First posted
Mar 13, 2014
StartActual
May 2014
Primary completionActual
May 2016
CompletionActual
May 2016
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02085538
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Mar 13, 2014
Start date
May 2014
Primary completion
May 2016
Completion
May 2016
Last update
Apr 30, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Palbociclib

Start the discussion